This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, J. Articles by Yu, J. S. Search for Related Content PubMed PubMed Citation Articles by Hu, J. Articles by Yu, J. S.

Induction of Potent Antitumor Immunity by Intratumoral Injection of Interleukin 23–Transduced Dendritic Cells

¹ Maxine Dunitz Neurosurgical Institute and ² Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California and ³ Department of Experimental Medicine, University of Perugia, Perugia, Italy

Requests for reprints: John S. Yu, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Suite 800 East, 8631 West 3rd Street, Los Angeles, CA 90048. Phone: 310-423-0845; Fax: 310-423-0810; E-mail: yuj{at}cshs.org.

Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in priming immune responses to tumor. Interleukin (IL)-23 can act directly on DC to promote immunogenic presentation of tumor peptide in vitro. Here, we evaluated the combination of bone marrow–derived DC and IL-23 on the induction of antitumor immunity in a mouse intracranial glioma model. DCs can be transduced by an adenoviral vector coding single-chain mouse IL-23 to express high levels of bioactive IL-23. Intratumoral implantation of IL-23–expressing DCs produced a protective effect on intracranial tumor–bearing mice. The mice consequently gained systemic immunity against the same tumor rechallenge. The protective effect of IL-23–expressing DCs was comparable with or even better than that of IL-12-expressing DCs. IL-23–transduced DC (DC-IL-23) treatment resulted in robust intratumoral CD8⁺ and CD4⁺ T-cell infiltration and induced a specific TH1-type response to the tumor in regional lymph nodes and spleen at levels greater than those of nontransduced DCs. Moreover, splenocytes from animals treated with DC-IL-23 showed heightened levels of specific CTL activity. In vivo lymphocyte depletion experiments showed that the antitumor immunity induced by DC-IL-23 was mainly dependent on CD8⁺ T cells and that CD4⁺ T cells and natural killer cells were also involved. In summary, i.t. injection of DC-IL-23 resulted in significant and effective systemic antitumor immunity in intracranial tumor–bearing mice. These findings suggest a new approach to induce potent tumor-specific immunity to intracranial tumors. This approach may have therapeutic potential for treating human glioma. (Cancer Res 2006; 66(17): 8887-96)

This article has been cited by other articles:

				S. Wilkie, G. Picco, J. Foster, D. M. Davies, S. Julien, L. Cooper, S. Arif, S. J. Mather, J. Taylor-Papadimitriou, J. M. Burchell, et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor J. Immunol., April 1, 2008; 180(7): 4901 - 4909. [Abstract] [Full Text] [PDF]

				I. Kryczek, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment J. Immunol., June 1, 2007; 178(11): 6730 - 6733. [Abstract] [Full Text] [PDF]